Department of Pharmacy, Sarhad University of Science & Technology, Peshawar, KPK, Pakistan.
Department of Pharmacy, Faculty of Biological Sciences, University of Malakand, Chakdara, 18000, KP, Pakistan.
Drug Des Devel Ther. 2020 Jun 3;14:2165-2178. doi: 10.2147/DDDT.S237420. eCollection 2020.
The current study was designed to synthesize derivatives of succinimide and compare their biological potency in anticholinesterase, alpha-glucosidase inhibition, and antioxidant assays.
In this research, two succinimide derivatives including ()-1-(2,5-dioxo-1-phenylpyrrolidin-3-yl) cyclohexanecarbaldehyde (Compound ) and ()-2-(()-2,5-dioxo-1-phenylpyrrolidin-3-yl)-2-phenylpropanal (Compound ) were synthesized using Michael addition. Both the compounds, ie, and were evaluated for in-vitro acetylcholinesterase (AChE), butyrylctcholinesterase (BChE), antioxidant, and α-glucosidase inhibitory potentials. Furthermore, molecular docking was performed using Molecular Operating Environment (MOE) to explore the binding mode of both the compounds against different enzymes. Lineweaver-Burk plots of enzyme inhibitions representing the reciprocal of initial enzyme velocity versus the reciprocal of substrate concentration in the presence of synthesized compounds and standard drugs were constructed using Michaelis-Menten kinetics.
In AChE inhibitory assay, compounds and exhibited IC of 343.45 and 422.98 µM, respectively, against AChE enzyme. Similarly, both the compounds showed IC of 276.86 and 357.91 µM, respectively, against BChE enzyme. Compounds and displayed IC of 157.71 and 471.79 µM against α-glucosidase enzyme, respectively. In a similar pattern, compound exhibited to be more potent as compared to compound in all the three antioxidant assays. Compound exhibited IC values of 297.98, 332.94, and 825.92 µM against DPPH, ABTS, and HO free radicals, respectively. Molecular docking showed a triple fold in the AChE and BChE activity for compound compared with compound . The compound 1 revealed good interaction against both the AChE and BChE enzymes which revealed the high potency of this compound compared to compound .
Both succinimide derivatives exhibited considerable inhibitory activities against cholinesterases and α-glucosidase enzymes. Of these two, compound revealed to be more potent against all the in-vitro targets which was supported by molecular docking with the lowest binding energies. Moreover, compound also proved to have antiradical properties.
本研究旨在合成琥珀酰亚胺衍生物,并比较它们在抗胆碱酯酶、α-葡萄糖苷酶抑制和抗氧化测定中的生物活性。
在这项研究中,使用迈克尔加成法合成了两种琥珀酰亚胺衍生物,即()-1-(2,5-二氧代-1-苯基吡咯烷-3-基)环己烷甲酰基(化合物)和()-2-(()-2,5-二氧代-1-苯基吡咯烷-3-基)-2-苯基丙醛(化合物)。评估了化合物和 对乙酰胆碱酯酶(AChE)、丁酰胆碱酯酶(BChE)、抗氧化和α-葡萄糖苷酶抑制潜能的影响。此外,使用分子操作环境(MOE)进行分子对接,以探索两种化合物与不同酶的结合模式。使用米氏动力学构建了酶抑制的Lineweaver-Burk 图,代表在合成化合物和标准药物存在下,以初始酶速度的倒数与底物浓度的倒数作图。
在 AChE 抑制测定中,化合物和 对 AChE 酶的 IC 分别为 343.45 和 422.98 μM。同样,两种化合物对 BChE 酶的 IC 分别为 276.86 和 357.91 μM。化合物和 对 α-葡萄糖苷酶的 IC 分别为 157.71 和 471.79 μM。以类似的方式,化合物在所有三种抗氧化测定中都表现出比化合物更强的效力。化合物对 DPPH、ABTS 和 HO 自由基的 IC 值分别为 297.98、332.94 和 825.92 μM。分子对接显示,化合物对 AChE 和 BChE 的活性增加了三倍,与化合物相比。化合物与 AChE 和 BChE 酶均显示出良好的相互作用,这表明与化合物相比,该化合物具有更高的效力。
两种琥珀酰亚胺衍生物均表现出对胆碱酯酶和α-葡萄糖苷酶的相当大的抑制活性。在这两种化合物中,化合物对所有体外靶标表现出更强的效力,这得到了与最低结合能的分子对接的支持。此外,化合物还证明具有抗自由基特性。